Topic: Myasthenia Gravis

Myasthenia Gravis

Sep 2021 | Assessment

Interventions of Interest: Eculizumab (Soliris®, Alexion Pharmaceuticals, Inc.) Efgartigimod (Argenx, Halozyme Therapeutics, and Zai Lab) Myasthenia gravis is a rare chronic autoimmune disorder in which the immune system produces antibodies that prevent acetylcholine from binding with acetylcholine receptors, ultimately resulting in muscle contraction. For more information, please contact Maggie O’Grady, Program Manager, at mogrady@icer.org. View the Key […]